Advertisements
Feeds:
Posts
Comments

Search Results for 'Nebivolol'

FDA Advisory votes against approving Actavis nebivolol/valsartan combo – The Pharma Letter

Posted in Uncategorized on September 12, 2014| Leave a Comment »


Bidness ETC FDA Advisory votes against approving Actavis nebivolol/valsartan combo The Pharma Letter Nebivolol (marketed in the USA as Bystolic by Actavis subsidiary Forest Labs) is indicated for the treatment of hypertension and is effective at… Source: http://www.thepharmaletter.com See on Scoop.it – Cardiotoxicity Advertisements

Read Full Post »

Bystolic’s generic Nebivolol – Positive Effect on circulating Endothelial Progenitor Cells Endogenous Augmentation

Posted in Biological Networks, Gene Regulation and Evolution, Cell Biology, Signaling & Cell Circuits, Chemical Biology and its relations to Metabolic Disease, Disease Biology, Small Molecules in Development of Therapeutic Drugs, Frontiers in Cardiology and Cardiovascular Disorders, Health Economics and Outcomes Research, HTN, Origins of Cardiovascular Disease, Pharmaceutical Analytics, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment, Pharmacotherapy of Cardiovascular Disease, Population Health Management, Genetics & Pharmaceutical, Resident-cell-based, tagged , , , , , , , , , on July 16, 2012| 26 Comments »


Bystolic’s generic Nebivolol – Positive Effect on circulating Endothelial  Progenitor Cells Endogenous Augmentation Curator: Aviva Lev-Ari, PhD, RN   Bystolic’s generic Nebivolol – FDA approved for Treatment of Hypertension since 2008 – Pharmacological agent hypothesized to have positive effect on circulating Endothelial  Progenitor Cells (cEPCs) endogenous augmentation: Low number of cEPCs found to be associated with […]

Read Full Post »

Top Articles by Number of e-Readers for All Days ending 2019-02-17

Posted in on February 17, 2019|


Top Articles by Number of e-Readers for All Days ending 2019-02-17 (Summarized)   All Time Title Views Home page / Archives 603,640 Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? 16,748 Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) 13,287 Paclitaxel vs […]

Read Full Post »

Dynamic Contents for LPBI Group’s PowerPoint Presentation

Posted in on February 17, 2019|


Dynamic Contents for LPBI Group’s PowerPoint Presentation   The source material used in the creation of LPBI Group’s PowerPoint Presentation is from Nomination for 2018 Yidan Prize, recognition in the field of MEDICAL education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2018/10/21/nomination-for-2018-yidan-prize-recognition-in-the-field-of-medical-education-development-of-curation-methodologies-for-scientific-content-2018-nominee-aviva-lev-ari-phd-rn/ WORK-in-PROGRESS   Challenges and Opportunities for […]

Read Full Post »

Article Title, Author/Curator’s Name and Article Views >1,000, 4/2012 – 1/2019 @pharmaceuticalintelligence.com

Posted in Academic Publishing, Big Data & Analytics, Curation, Curation methodology, De novo synthesis, Dialectic, Discovery process, Evolutionary cognition, Experimental validation, Explanatory, Historical relevance, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management, Open Access Journals, Scientific Publishing, Scientist: Career considerations, Technology Advance Assessment of, Theoretic convergence on January 30, 2019| Leave a Comment »


Article Title, Author/Curator’s Name and Article Views >1,000, 4/2012 – 1/2019 @pharmaceuticalintelligence.com   Reporter: Aviva Lev-Ari, PhD, RN   Expert, Author, Writer’s Initials Name & Bio Roles @LPBI Group LHB Larry Bernstein, MD, FACP,   Member of the Board Expert, Author, Writer – All Specialties of Medicine & Pathology Content Consultant to Series B,C,D,E Editor, Series […]

Read Full Post »

Nomination for 2018 Yidan Prize, recognition in the field of MEDICAL education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN

Posted in LPBI Group Founder - Aviva Lev-Ari on October 21, 2018| Leave a Comment »


Nomination for 2018 Yidan Prize, recognition in the field of MEDICAL education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN   March 31, 2018 Yidan Prize for Education Development recognizes innovative ideas that tackle pressing challenges in the field of education. Nomination for recognition as means in tackling challenges […]

Read Full Post »

Data Science is the Greatest Science! It is the Greatest Science for Women, as well

Posted in Big Data & Analytics, Data Science, Scientist: Career considerations, Women in Life Sciences on March 12, 2018| Leave a Comment »


Data Science is the Greatest Science! It is the Greatest Science for Women, as well Curator: Aviva Lev-Ari, PhD, RN   UPDATED ON 3/2/2018 The Growing Influence of Analytics on the C-Suite     This curation has three parts: Part 1: Account of a Data Scientist, Aviva Lev-Ari, PhD – worked in Data Science, 1976-2005 […]

Read Full Post »

Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018

Posted in Award Nominations, LPBI Group Founder - Aviva Lev-Ari, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management on March 6, 2018| 5 Comments »


Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018   Prepared for publication in American Friends of the Hebrew University (AFHU), May 2018 Newsletter, Hebrew University’s HUJI Alumni Spotlight Section. The profile was up on 5/3/2018 on AFHU website under the Alumni Spotlight at https://www.afhu.org/ Excerpts were Published in AFHU e-news on 5/11/2018. https://us10.campaign-archive.com/?u=5c25136c60d4dfc4d3bb36eee&id=757c5c3aae&e=d09d2b8d72 https://www.afhu.org/2018/05/03/aviva-lev-ari/ Aviva Lev-Ari, PhD, RN – February […]

Read Full Post »

CHI’s Discovery on Target, Sheraton Boston, Sept. 25-28, 2018

Posted in Conference Coverage with Social Media, Drug Delivery Platform Technology, Drug Development Process, Drug Discovery Chemistry, Personalized and Precision Medicine & Genomic Research, Pharmaceutical Analytics, Pharmaceutical Discovery, Pharmaceutical Drug Discovery, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Informatics, Pharmaceutical R&D Investment, Pharmacodynamics and Pharmacokinetics, Pharmacogenomics, Pharmacologic toxicities on February 21, 2018| Leave a Comment »


CHI’s Discovery on Target, Sheraton Boston, Sept. 25-28, 2018 Reporter: Aviva Lev-Ari, PhD, RN   ANNOUNCEMENT Leaders in Pharmaceutical Business Intelligence (LPBI) Group is a selected CHI Business Partner for Media Communication for this event as well a provider of REAL TIME PRESS COVERAGE for this cardinal event in the domain of  Drug Discovery and Drug Delivery. Dr. Aviva […]

Read Full Post »

Updated on 4/14/2019 –>> FIVE years of e-Scientific Publishing @pharmaceuticalintellicence.com, Top Articles by Author and by e-Views >1,000, 4/27/2012 to 1/29/2018

Posted in LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management on April 28, 2017| Leave a Comment »


Updated on 4/14/2019 –>> FIVE years of e-Scientific Publishing @pharmaceuticalintellicence.com, Top Articles by Author and by e-Views >1,000, 4/27/2012 to 1/29/2018 UPDATED on 4/14/2019 Top Posts for all days ending 2019-04-14 (Summarized) All Time Title Views Home page / Archives 615,383 Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century […]

Read Full Post »

Next »